PubMed Health⌕ Search

Biomedical subjects

E Billaud-Mesguich

Publications and source records attributed to E Billaud-Mesguich.

4 recordsLinked to original sources
PubMed1987

[Measurement of platelet catecholamine content for the diagnosis of pheochromocytoma with intermittent hypertension].

We have compared platelet and plasma catecholamines (radioenzymatic assay with catechol-O-methyl transferase) and urinary metanephrines (high performance liquid chromatography) in 16 patients with phaeochromocytoma, 12 essential hypertensives, and 15 normotensive volunteers. Hypertensive patients with or without phaeochromocytoma had labile or paroxysmal hypertension with normal or borderline blood pressures between paroxysms. Catecholamine concentrations in platelets and plasma did not differ in essential hypertensives and controls, but were higher in patients with phaeochromocytoma than in subjects without tumour, with values overlapping between groups. Metanephrine excretion was markedly higher in phaeochromocytoma than in essential hypertension, with no intergroup overlap. Platelet adrenaline plus noradrenaline content was highly correlated to urinary metanephrines (r' = 0.830, n = 28 p less than 0.01). Using as a cut-off point the highest values measured in essential hypertensives, the sensitivity of each measurement was 1.00 for metanephrines, 0.87 for platelet catecholamines and 0.50 or less for plasma catecholamines. Measurement of platelet catecholamine content is a sensitive test and an appropriate alternative to metanephrine measurement in the difficult cases of suspected phaeochromocytoma with intermittent hypertension.

Adrenal Gland Neoplasms↗
PubMed1986

[Pharmacokinetics of enalapril].

Enalaprilate, an antihypertensive agent that inhibits angiotensin-converting enzyme activity, is not directly absorbable. It is therefore administered as an inactive precursor, an énalaprilate ester which is hydrolysed in vivo with an ultimate bioavailability of 30-40 p. 100. Enalaprilate is entirely excreted through the kidney. With repeated administrations steady state is rapidly reached, and the drug does not accumulate. The effective half-life is 10 hours. Kinetics are linear and depend on renal function. These data, obtained in healthy volunteers with 10 mg doses, also apply to hypertensive patients receiving 20 mg. Following a 20 mg per day dose a more than 50 p. 100 inhibition of the angiotensin-converting enzyme is maintained for 24 hours. In patients with moderate renal impairment or in elderly people (creatinine clearance greater than 30 ml/min), plasma concentrations are slightly increased and there is no need for dosage adjustment. In patients with severe renal impairment (creatinine clearance less than or equal to 30 ml/min) plasma concentrations are considerably increased with a risk of strong accumulation, and dosage must be reduced to 5 or 2.5 mg per day.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1986

[Clinical pharmacology of enalapril in hypertension with chronic renal failure].

The effects of a single oral dose of enalapril (20 mg) on blood pressure (BP), heart rate (HR) plasma renin activity (PRA) aldosterone (PA), converting enzyme inhibition (CEI) and enalaprilat (E, active metabolite) were investigated during 96 h in 3 groups of 5 hypertensive patients with (1) normal renal function (creatinine clearance: Clcr greater than 80 ml.min-1); (2) moderate chronic renal failure: 80 greater than or equal to Clcr greater than 30 ml.min-1; (3) severe chronic renal failure: 30 greater than or equal to Clcr greater than 10 ml.min-1. Results are as follows (mean +/- SEM): (Table: see text) CEmax: maximal plasma concentration; TEmax: delay corresponding to CEmax; TE 1/2: plasma elimination half-life; AUCE: area under plasma level versus time curve. a: p less than 0.01; b: p less than 0.001; versus (1). In the 3 groups, CEI reached 87-94% as early as the 3rd h; however, at 96 h, CE1 was higher in (3) than in (1) and (2): 77.6 +/- 3.3% versus 6.0 +/- 1.6 and 17.7 +/- 4.8 (p less than 0.001 respectively). In (3). PRA increased at the 1st h and remained elevated: at 96 h, delta PRA was + 3.0 +/- 2.9 ng.ml-1 -.h-1 in (3) versus + 0.10 +/- 0.06 and + 0.25 +/- 0.17 ng.ml-1.h-1 .n (1) and (2) [(3) versus (1): p less than 0.01]; delta PA was lower in (3): -4.56 +/- 2.01 ng. 100 ml-1 versus -0.54 +/- 0.31 and -2.50 +/- 0.38 ng. 100 ml-1 [(3) versus (1): p less than 0.05].(ABSTRACT TRUNCATED AT 250 WORDS)

Aldosterone↗